Faculty Opinions recommendation of Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation.

2006 ◽  
Author(s):  
Pierre Ferrier
Keyword(s):  
Cell Differentiation ◽  
Plasma Cell ◽  
Interferon Regulatory Factor ◽  
Regulatory Factor ◽  
Isotype Switching ◽  
Plasma Cell Differentiation ◽  
Interferon Regulatory Factor 4

scholarly journals Graded Expression of Interferon Regulatory Factor-4 Coordinates Isotype Switching with Plasma Cell Differentiation

Immunity ◽  
2006 ◽  
Vol 25 (2) ◽  
pp. 225-236 ◽  
Author(s):  
Roger Sciammas ◽  
A.L. Shaffer ◽  
Jonathan H. Schatz ◽  
Hong Zhao ◽  
Louis M. Staudt ◽  
...  
Keyword(s):  
Cell Differentiation ◽  
Plasma Cell ◽  
Interferon Regulatory Factor ◽  
Regulatory Factor ◽  
Isotype Switching ◽  
Plasma Cell Differentiation ◽  
Interferon Regulatory Factor 4

scholarly journals Dysregulated T helper cell differentiation in the absence of interferon regulatory factor 4

2002 ◽  
Vol 99 (18) ◽  
pp. 11808-11812 ◽  
Author(s):  
M. Lohoff ◽  
H.-W. Mittrucker ◽  
S. Prechtl ◽  
S. Bischof ◽  
F. Sommer ◽  
...  
Keyword(s):  
Cell Differentiation ◽  
Interferon Regulatory Factor ◽  
T Helper Cell ◽  
Helper Cell ◽  
T Helper ◽  
Regulatory Factor ◽  
Interferon Regulatory Factor 4

scholarly journals Immunohistochemical Labeling of Multiple Myeloma Oncogene 1/Interferon Regulatory Factor 4 (MUM1/IRF-4) in Canine Cutaneous Histiocytoma

2018 ◽  
Vol 55 (4) ◽  
pp. 517-520 ◽  
Author(s):  
Justin M. Stilwell ◽  
Daniel R. Rissi
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cell ◽  
Interferon Regulatory Factor ◽  
Round Cell ◽  
Regulatory Factor ◽  
Diagnostic Challenge ◽  
Poorly Differentiated ◽  
Interferon Regulatory Factor 4 ◽  
Round Cell Tumors

Multiple myeloma oncogene 1/interferon regulatory factor 4 (MUM1/IRF-4) immunohistochemistry (IHC) is mainly used for diagnostic confirmation of plasma cell tumors (PCTs) in dogs and cats. This article describes MUM1/IRF-4 IHC expression in 20 cases of canine cutaneous histiocytoma (CH) and compares it with 10 cutaneous or mucocutaneous PCTs and 5 cutaneous histiocytic sarcomas (HSs) submitted to the same IHC protocol. All histiocytomas had strong nuclear and variable cytoplasmic immunolabeling for MUM1/IRF-4, whereas all PCTs had strong nuclear and moderate cytoplasmic immunolabeling for MUM1/IRF-4. No MUM1/IRF-4 immunolabeling was detected in the HSs. Although not typically a diagnostic challenge, MUM1/IRF-4 expression may have to be used with caution or in conjunction with additional immunomarkers to differentiate among poorly differentiated round cell tumors, especially when a histiocytic or plasma cell origin is suspected.

Sign in / Sign up

Export Citation Format

Share Document